Barbara Troupin

Dr. Barbara Troupin is a pharmaceutical executive with over 25 years of experience in the industry. Barbara is currently the Director at Equillium, and previously held senior positions at MyoKardia, Athena Alliance, and Aquinox Pharmaceuticals, Inc.

Dr. Troupin’s career has been defined by their ability to build and lead high-performing teams that are focused on delivering results. At Aquinox, they more than doubled the size of the clinical development, regulatory, and medical affairs teams and led the company through a period of rapid growth. Under their leadership, the company successfully completed Phase 3 clinical studies and partnered with a Japanese company for $25M upfront with total development/commercial milestones of more than $150M.

At MyoKardia, Dr. Troupin served as the Senior Vice President of Medical Affairs where they were responsible for providing strategic direction to the medical affairs team. In this role, they oversaw all aspects of the medical affairs function including clinical research, scientific communications, and medical education.

Dr. Troupin is a frequent speaker at industry conferences and has been published in numerous peer-reviewed journals. Barbara received their MD from Columbia University College of Physicians and Surgeons and completed their residency in Internal Medicine at Brigham and Women’s Hospital.

Barbara Troupin has an MD from the University of Pennsylvania School of Medicine, an MBA from The Wharton School, and a BA from University of California, San Diego. Barbara also has a certification from the American Board of Obesity Medicine and is a residency trained family physician.